Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines ; volume:11 ; number:1 ; day:12 ; month:12 ; year:2012 ; pages:1-14 ; date:12.2012
Molecular cancer ; 11, Heft 1 (12.12.2012), 1-14, 12.2012
- Creator
-
Cavazzoni, Andrea
Alfieri, Roberta R.
Cretella, Daniele
Saccani, Francesca
Ampollini, Luca
Galetti, Maricla
Quaini, Federico
Graiani, Gallia
Madeddu, Denise
Mozzoni, Paola
Galvani, Elena
La Monica, Silvia
Bonelli, Mara
Fumarola, Claudia
Mutti, Antonio
Carbognani, Paolo
Tiseo, Marcello
Barocelli, Elisabetta
Petronini, Pier Giorgio
Ardizzoni, Andrea
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-11-91
- URN
-
urn:nbn:de:101:1-2021081520494648406673
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cavazzoni, Andrea
- Alfieri, Roberta R.
- Cretella, Daniele
- Saccani, Francesca
- Ampollini, Luca
- Galetti, Maricla
- Quaini, Federico
- Graiani, Gallia
- Madeddu, Denise
- Mozzoni, Paola
- Galvani, Elena
- La Monica, Silvia
- Bonelli, Mara
- Fumarola, Claudia
- Mutti, Antonio
- Carbognani, Paolo
- Tiseo, Marcello
- Barocelli, Elisabetta
- Petronini, Pier Giorgio
- Ardizzoni, Andrea
- SpringerLink (Online service)
Other Objects (12)
Ramucirumab (NSCLC, Kombination mit Erlotinib) : Nutzenbewertung gemäß § 35a SGB V
Erlotinib in pancreatic cancer
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation–Positive NSCLC
Erlotinib beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom (NSCLC) : klinische Evaluation im Rahmen einer Phase IV Studie (Tarceva EAP)
Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Ramucirumab (NSCLC, Kombination mit Erlotinib) : Nutzenbewertung gemäß § 35a SGB V
Erlotinib in pancreatic cancer
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation–Positive NSCLC
Erlotinib beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom (NSCLC) : klinische Evaluation im Rahmen einer Phase IV Studie (Tarceva EAP)
Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Ramucirumab (NSCLC, Kombination mit Erlotinib) : Nutzenbewertung gemäß § 35a SGB V
Erlotinib in pancreatic cancer
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation–Positive NSCLC
Erlotinib beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom (NSCLC) : klinische Evaluation im Rahmen einer Phase IV Studie (Tarceva EAP)
Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship